Casak SJ, Horiba MN, Yuan M, Cheng J, et al. FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer. Clin Cancer Res 2023 Jun 15:CCR-23-1041. doi: 10.1158/1078-0432.CCR-23-1041.
PMID: 37318379